Clinical Trials Directory

18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques

The primary objective is to compare the diagnostic performance of 18F- Fluoride PET/CT scanning to that of conventional bone scanning for detecting cancer that has spread to the bone (bone metastasis). The intent of the study is to determine whether 18F-Fluoride PET/CT will lead to improved treatment and patient outcomes.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • device : Bone Scan: F18-Fluoride PET/CT or TC-MDP

Phase: Phase 3


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Patient is ? 18 years old at the time of the drug administration (Patient may be male or female of any race / ethnicity.) - Patient or patient's legally acceptable representative cognitively provides written informed consent - Patients without known bone metastases who are newly diagnosed with ? stage 3 breast cancer, ? stage 3 lung cancer, or ? stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer - Patient is scheduled to undergo a conventional bone scan - Patient is capable of complying with study procedures - Patient is able to remain still for duration of imaging procedure (about one hour) - Patient may have had a prior PET or PET/CT scan for staging/restaging.

External Links

Footer Links: